Hummingbird Bioscience
Hummingbird Bioscience
Hummingbird Bioscience
  • About Us
  • Science
    • ADC Platform
    • Antibody Platform
    • Publications
  • Pipeline
    • HMBD-001
    • HMBD-501
  • News
  • Partnering
  • Patients
  • Contact
  • Join Us

    RelatedNews-HMBD-501

  • All
  • News
  • Publications & Posters
    • News
    • News - 2026

    Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

    Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet…

    Continue Reading
    • HMBD-501
    • Posters
    • Posters - 2023
    • Publications & Posters

    AACR 2023: HMBD-501 – a novel Fc engineered, exatecan-based next-generation HER3-targeting Antibody-Drug Conjugate (ADC) shows robust tolerability and efficacy in pre-clinical solid tumor models

    Continue Reading
    • News
    • News - 2023

    Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023

    Continue Reading

Hummingbird Bioscience

The Galen
61 Science Park Road, #06-15
Singapore 117525


Hummingbird Bioscience Twitter Hummingbird Bioscience Twitter Hummingbird Bioscience LinkedinHummingbird Bioscience Linkedin Hummingbird Bioscience YouTube Hummingbird Bioscience YouTube
Subscribe to our updates
Registered Company No: 201505192N
PRIVACY POLICY | © 2025 Hummingbird Bioscience
  • About Us
  • Science
    • ADC Platform
    • Antibody Platform
    • Publications
  • Pipeline
    • HMBD-001
    • HMBD-501
  • News
  • Partnering
  • Patients
  • Contact
  • Join Us

What are you looking for?

Subscribe to our updates

    *indicates required

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

    Close